199 related articles for article (PubMed ID: 29361853)
1. Advances in prodrug design for Parkinson's disease.
Cacciatore I; Ciulla M; Marinelli L; Eusepi P; Di Stefano A
Expert Opin Drug Discov; 2018 Apr; 13(4):295-305. PubMed ID: 29361853
[TBL] [Abstract][Full Text] [Related]
2. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.
D'Aurizio E; Sozio P; Cerasa LS; Vacca M; Brunetti L; Orlando G; Chiavaroli A; Kok RJ; Hennink WE; Di Stefano A
Mol Pharm; 2011 Dec; 8(6):2408-15. PubMed ID: 22014118
[TBL] [Abstract][Full Text] [Related]
4. Antiparkinson prodrugs.
Di Stefano A; Sozio P; Cerasa LS
Molecules; 2008 Jan; 13(1):46-68. PubMed ID: 18259129
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Ravani L; Sarpietro MG; Esposito E; Di Stefano A; Sozio P; Calcagno M; Drechsler M; Contado C; Longo F; Giuffrida MC; Castelli F; Morari M; Cortesi R
Mater Sci Eng C Mater Biol Appl; 2015 Mar; 48():294-300. PubMed ID: 25579926
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
8. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
Haddad F; Sawalha M; Khawaja Y; Najjar A; Karaman R
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295587
[No Abstract] [Full Text] [Related]
9. New drug delivery strategies for improved Parkinson's disease therapy.
Di Stefano A; Sozio P; Iannitelli A; Cerasa LS
Expert Opin Drug Deliv; 2009 Apr; 6(4):389-404. PubMed ID: 19382882
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
Contin M; Riva R; Albani F; Baruzzi A
Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
Stocchi F; Vacca L; Stirpe P; Torti M
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1189-1195. PubMed ID: 30479171
[TBL] [Abstract][Full Text] [Related]
12. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
[TBL] [Abstract][Full Text] [Related]
13. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
Okereke CS
J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
[TBL] [Abstract][Full Text] [Related]
14. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
Harder S; Baas H; Rietbrock S
Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
Dézsi L; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
18. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
19. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Kestenbaum M; Fahn S
Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
[TBL] [Abstract][Full Text] [Related]
20. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Simms SL; Huettner DP; Kortagere S
Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
